McGowan JP, Shah SS. Prevention of perinatal HIV transmission during pregnancy. J Antimicrob Chemother.2000;46:657-668.
Rouzioux C, Costagliola D, Burgard M.
et al. Estimated timing of mother-to-child human immunodeficiency virus type
1 transmission by use of a Markov model. Am J Epidemiol.1995;142:1330-1337.
Connor EM, Sperling RS, Gelber R.
et al. Reduction of maternal-infant transmission of the human immunodeficiency
virus type 1 with zidovudine treatment. N Engl J Med.1994;331:1173-1180.
Stiehm ER, Lambert JS, Mofenson LM.
et al. Efficacy of zidovudine and hyperimmune HIV immunoglobulin for reducing
perinatal HIV transmission from HIV-infected women with advanced disease. J Infect Dis.1999;179:567-575.
Cooper ER, Nugent RP, Diaz C.
et al. After AIDS Clinical Trials Group 076: the changing pattern of zidovudine
use during pregnancy, and the subsequent reduction in the vertical transmission
of human immunodeficiency virus in a cohort of infected women and their infants. J Infect Dis.1996;174:1207-1211.
Mayaux M-J, Teglas J-P, Mandelbrot L.
et al. Acceptability and impact of zidovudine for prevention of mother-to-child
human immunodeficiency virus-1 transmission in France. J Pediatr.1997;131:857-862.
Mirochnick M, Fenton T, Gagnier P.
et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type
1-infected pregnant women and their neonates. J Infect Dis.1998;178:368-374.
Musoke P, Guay L, Bagenda D.
et al. A phase I/II study of the safety and pharmacokinetics of nevirapine
in HIV-infected Ugandan women and their neonates (HIVNET 006). AIDS.1999;13:479-486.
Guay LA, Musoke P, Fleming T.
et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine
for prevention of mother-to-child transmission of HIV in Kampala, Uganda. Lancet.1999;354:795-802.
Mayaux MJ, Blanche S, Rouzioux C.
et al. Maternal factors associated with perinatal HIV transmission. J Acquir Immune Defic Syndr.1995;8:188-194.
European Collaborative Study. HIV-infected pregnant women and vertical transmission in Europe since
Division of AIDS, National Institute of Allergy and Infectious Diseases. DAIDS Virology Manual for HIV Laboratories. Washington, DC: US Dept of Health and Human Services; 1997. Publication
Hollinger FB, Bremer JW, Myers LE.
et al. Standardization of sensitive human immunodeficiency virus coculture
procedures and establishment of a multicenter quality assurance program for
the AIDS Clinical Trials Group. J Clin Microbiol.1992;30:1787-1794.
Yen-Lieberman B, Brambilla D, Jackson B.
et al. Evaluation of a quality assurance program for quantitation of human
immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group
virology laboratories. J Clin Microbiol.1996;34:2695-2701.
Not Available. StatXact, Version 4.0. Cambridge, Mass: Cytel Software Corp; 2000.
Bryson YJ, Luzuriaga K, Sullivan JL, Wara DW. Proposed definitions for in utero versus intrapartum transmission of
HIV [letter]. N Engl J Med.1992;327:1246-1247.
Morris AB, Cu-Uvin S, Harwell JI.
et al. Multicenter review of protease inhibitors in 89 pregnancies. J Acquir Immune Defic Syndr.2000;25:306-311.
Cooper ER, Charurat M, Burns DN.
et al. Trends in antiretroviral therapy and mother-infant transmission of
HIV. J Acquir Immune Defic Syndr.2000;24:45-47.
International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human
immunodeficiency virus type 1. N Engl J Med.1999;340:977-987.
Mandelbrot L, Landreau-Mascaro A, Rekacewicz C.
et al. Lamivudine-zidovudine combination for the prevention of maternal-infant
transmission of HIV. JAMA.2001;285:2083-2093.
Moodley D. The SAINT trial: nevirapine versus zidovudine + lamivudine (3TC) in
prevention of peripartum HIV transmission. From: XIII International AIDS Conference; July 9-14, 2000; Durban,
South Africa. Abstract LbOr2.
McIntyre J.for the SAINT Study Team. Evaluation of safety of two simple regimens for prevention of mother
to child transmission (MCTC) of HIV infection. From: XIII International AIDS Conference; July 9-14, 2000; Durban,
South Africa. Abstract TuOrB356.
Eshleman SH, Becker-Pergola G, Deseyve M.
et al. Impact of human immunodeficiency virus type 1 (HIV) subtype on women
receiving single-dose nevirapine prophylaxis to prevent HIV vertical transmission
(HIV network for prevention trials 012 study). J Infect Dis.2001;184:914-917.
Eshelman SH, Mracna M, Guay LA.
et al. Selection and fading of resistance mutations in women and infants receiving
nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS.2001;15:1951-1957.
Cunningham CK, Britto P, Gelber R.
et al. Genotypic resistance analysis in women participating in PACTG 316 with
HIV RNA >400 copies/mL. From: 8th Conference on Retroviruses and Opportunistic Infections;
February 4-8, 2001; Chicago, Ill. Abstract 712.
Chaix ML, Rekacewicz C, Bazin B.
et al. Genotypic resistance analysis in French women participating in PACTG
316/ANRS 083. From: 8th Conference on Retroviruses and Opportunistic Infections;
February 4-8, 2001; Chicago, Ill. Abstract 470.